Background {#Sec1}
==========

Human papillomavirus (HPV) is a common sexually transmitted infection and is one of the major causes of infection-related cancer worldwide \[[@CR1]\]. Globally, the prevalence of HPV infection in women with normal cytology is 11--12% and sub-Saharan Africa (SSA) has the highest prevalence rate, 24% \[[@CR2]\]. There is regional variation in HPV-related disease burden in SSA with Eastern and Western regions of the continent having the highest burden \[[@CR2]\]. In 2008, 12.7 million new cancer cases were reported globally and of these, 610,000 were attributable to HPV infection \[[@CR3]\]. The incidence and mortality was significantly higher in developing countries compared to developing countries.. HPV-related disease burden is expected to rise in the next 20 years in this SSA because of the aging population and growth, which is compounded by the HIV epidemic, especially in the Southern African region \[[@CR3], [@CR4]\].

High-risk HPV (hr-HPV) prevalence rate remains highest in HIV-infected individuals despite the increasing coverage of combination antiretroviral therapy (cART) \[[@CR4]--[@CR8]\]. HIV infection leads to a reduction in CD4 T-cells, which are important for the resolution of HPV infection \[[@CR5], [@CR6]\]. HPV infection has been reported to persist longer in HIV-infected patients and this often leads to development of cancerous lesions' \[[@CR9], [@CR10]\]. Other studies suggest that anogenital HPV infection is associated with increased acquisition of HIV \[[@CR11]--[@CR16]\]. In a study conducted on HIV-positive patients with vulvar cancer in Botswana, oncogenic viruses were associated with vulvar cancer \[[@CR17]\]. However, younger women with HPV infection have been found to be at a lower risk of developing vulvar cancer as HPV infection appears to be self-limiting \[[@CR18]\].

More than 120 HPV genotypes have been identified and these are categorized as either high-risk/oncogenic or low-risk HPV types, based on their aetiological association with squamous cell carcinoma (SCC) of the cervix \[[@CR19], [@CR20]\]. High-risk HPVs have received the most attention in many countries in the past decade especially HPV types 16 and HPV 18. This is because many studies have found these two types to be associated with about 99.7% of cervical cancers, 91% of anal cancers and 71% of vaginal cancers especially in the developed world \[[@CR21], [@CR22]\]. In SSA, there is limited data on HPV-related diseases such as; vulvar, vagina, anus and penis cancer due to other hr.-HPV types besides HPV 16 and HPV 18, as compared to cervical cancer.

It is also reported that, although HPV types 16 and 18 are the most common, others hr.-HPV types such as HPV 45, 35 and 58 are being detected more frequently in SSA \[[@CR2]\]. HPV prevalence has also been reported to be high amongst men in SSA and this could the reason for high cervical and penile cancer rates in this part of the world \[[@CR23]\]. The low-risk HPV types are mainly associated with genital warts and oral papilloma \[[@CR24]\].

To date, there is no known cure for HPV infection and prevention via vaccination remains the bulwark against some of the hr.-HPV types. The quadrivalent Gardasil vaccine (Merck Company, USA) protects against HPV types 6, 11, 16 and 18. However, Cervarix vaccine *(*GlaxoSmithKline*,* USA) provides cross-protection against HPV types; 26, 18, 31, 33 and 45 \[[@CR25]\]. A new 9-valent HPV vaccine Gardasil (Merck Company, USA) that provides cross-protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 is now available \[[@CR25]\]. The most prevalent HPV type worldwide is HPV 16 and there is less variation in the geographical distribution of HPV 16 than other types \[[@CR22]\]. Variations in HPV types present in different regions could affect regional vaccine effectiveness.

Studies comparing invasive cervical cancers in Botswana, Kenya and United States have demonstrated differences in HPV type distribution, which may be driven by HIV infection \[[@CR26], [@CR27]\]. Data on the association between anogenital cancers and HPV diversity in Botswana is limited \[[@CR28]\]. Our study sought to determine the prevalence of oncogenic HPV genotype in patients with anogenital malignancies in Botswana. Previous studies have documented HPV genotypes in cervical cancer and precursor lesions mostly amongst HIV infected individuals \[[@CR26], [@CR27], [@CR29], [@CR30]\].

The incidence of HPV-associated cancers is increasing by an estimated 3.9% per year in Botswana and this increase has been primarily associated with HIV co-infection \[[@CR4]\]. Treatment with HAART does not seem to decrease the cancer incidence in the HIV infected population and as life expectancy improves, cancer incidence seems to be also increasing due to the aging population \[[@CR4]\]. The importance of HPV types in the development of cancer lesions needs further investigation in Botswana in order to better understand the epidemiology of HPV infections. To our knowledge, this study is the first to report prevalence of oncogenic HPV types in anogenital cancers in Botswana.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

This was a retrospective cross-sectional study that used residual Formalin Fixed Paraffin Embedded (FFPE) tissue material from 137 patients diagnosed with anogenital cancers who attended public health facilities for diagnostic and treatment services in the southern part of Botswana during the years, 2004 to 2006 and 2013 to 2016. Anogenital cancer diagnosis was made by the Anatomical Pathologist at the Botswana's Ministry of Health and Wellness National Health Laboratory: a reference laboratory providing pathology services to southern Botswana. Demographic data, and clinical data on the anatomical site of the tissue sampled, HIV status, histopathology result, and year of diagnosis was obtained from the patients' pathology reports. The specimens were de-identified for the purposes of this study. The Ethical Review board of University of Botswana, and the Ministry of Health's Research and Development Committee (HRDC) approved this study. We obtained permission to access the specimens from the National Health Laboratory.

DNA extraction {#Sec4}
--------------

Each tissue block was cooled at −3.5 °C before a 20 μm thick section were cut and processed for DNA extraction. The first 20 μm tissue section for each block was discarded to ensure consecutive cleaner sections were collected. To avoid contamination between different participants, specimens during sectioning, the microtome stage and blade were cleaned with xylene followed by absolute alcohol and DNA/RNA AWAY solution after each tissue block section.

The tissue samples were incubated overnight in 15 ml of xylene to ensure complete removal of paraffin wax from the tissue, followed by three one-hour washes in absolute alcohol to clear xylene. Gradual re-hydration of the tissue sections was done by successional one-hour incubations in 95%, 80%, and 70% alcohol.

Tissue sections were incubated in distilled water overnight before digestion. Tissue digestion was achieved by adding 600 μL of Nuclisens lysis buffer (bioMerieux SA, France) and 200 μL of proteinase-K enzyme (Thermo Fisher Scientific, USA) to the tissue section. This was mixed by vortexing, followed by pulse centrifugation and overnight incubation at 56 °C. Tissue digests were incubated at 100 °C to de-activate the Proteinase-K enzyme before centrifugation at 3, 500 rpm for 5 min. After centrifuging, 700 μL of the lysate was transferred into Abbott RealTi*m*e HR HPV assay reaction vessel for DNA isolation using the *m*Sample Preparation System DNA kit on the Abbott *m*2000*sp* instrument, following the manufacturer's instructions.

HR HPV genotyping {#Sec5}
-----------------

The Abbott RealTi*m*e HR HPV assay (Abbott GmbH & Co. KG, Wiesbaden, Germany) qualitatively detects DNA from 14 high-risk human papillomavirus genotypes using modified GP5+/6+ primer mix consisting of three forward primers and two reverse primers targeting the conserved L1 region of HPV and an internal control (IC) primer pair targets a human β-globin sequence. The Abbott RealT*ime* HR HPV assay provides specific probes that are differentially labelled qualitatively detect of HPV16 and HPV18, and an evaluation of the human beta-globin internal control. Probes for hr.-HPV types 31, 33, 35, 39, 45, 51, 52, 56, 56, 59, 66 and 68 are labelled with the same dye, and presence of any of these genotypes is reported as Other HR detected \[[@CR31]\].

All tissues with other hr.-HPV types detected using the Abbott RealTi*me,* were subsequently analysed using an in-house multiplex qPCR assay. This assay uses 15 validated fluorophoreprobes in order to differentiate specific hr.-HPV types. To validate our methods and results, 26 h-HPV positive and 10 h-HPV negative known samples from previous HPV studies were included as controls from extraction to genotyping. Their previous results were confirmed by our methods. The in-house hr.-HPV testing was performed as a triplex where each well of a 96 well PCR plate contained primers and probes for two HPV types in addition to human genomic DNA control (β-globin). The real-time PCR reactions were setup in 20 μL total volumes containing 10 μL KAPA Probe Force qPCR Master Mix (KAPA Biosystems, MA, USA) and HPV primer and probe mix, as well as 10 μL of the extracted DNA template. The PCR reactions were run on the ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA); starting with the pre-PCR hold at 98 °C for 10 min, followed by 5 cycles at 95 °C for 10 s, 50 °C for 20 s and 72 °C for another 20 s. The last stage was 95 °C for 10 s, followed by 45 cycles in 1 min at 60 °C before holding indefinitely at 60 °C. Two or three replicates with concordant detection of the HPV types being tested were considered true positives. Results were considered valid only if the human genomic DNA control (β-globin) was positive.

Statistical analysis {#Sec6}
--------------------

Prevalence estimates were presented with 95% confidence intervals calculated using the binomial exact methods. Fisher's exact tests were used to compare prevalence by selected categorical variables such as HIV status, HPV DNA extraction and HPV type. Data was first managed using the Microsoft Excel spreadsheets and all analysis was conducted using STATA version 14.2 (College Station, TX).

Results {#Sec7}
=======

A total of 126/137 (92%) FFPE tissue blocks had amplifiable DNA as measured by the successful detection of the human ß-globin gene. Samples were obtained from individuals with squamous cell carcinoma, of which 21 (16.7%), 31 (24.6%) and 74 (58.7%) were from anal, penile, and vulvar biopsies, respectively. The median age was 44 years (IQR: 39, 56) (Table [1](#Tab1){ref-type="table"}). Among the anal specimens, 9 (43%) were from males and 12(57%) were from females (Table [1](#Tab1){ref-type="table"}). Ninety-three (73.8%) patients had their HIV status documented in the records while the rest did not. 83 out of 93 were HIV positive, a prevalence of 89.4% (95% CI: 81--94).Table 1Demographic and laboratory characteristics of the study populationAge (median; IQR)44 years (39--56)Gender Female, n (%)87 (69) Male, n (%)39 (31)Anatomical sites*n* = 126 Anal, n (%)21 (16.7) Penile, n (%)31 (24.6) Vulvar, n (%)74 (58.7)HIV status HIV negative, n (%)10 (7.9) HIV positive, n (%)83 (65.9) Unknown status, n (%)33 (26.2)

High-risk HPV was detected in 68/126 tissues, a prevalence of 54% (95% CI: 44.9--62.9), Table [2](#Tab2){ref-type="table"}. High-risk HPV was most frequently detected in anal SCC (62%), followed by vulvar SCC (58%) and penile SCC (42%), Table [3](#Tab3){ref-type="table"}. There was no statistically significant difference observed in hr.-HPV prevalence in the different anatomical sites (*P* = 0.274; Fisher's exact). Overall HPV 16 prevalence was 69% (95% CI: 58--80). The highest HPV 16 prevalence was observed in vulvar SCC at 81% (34/42), followed by anal SCC at 62% (8/13) and the lowest prevalence was observed in penile SCC at 39% (5/13). The presence of HPV 16 was statistically marginally associated with anatomical site (*P* = 0.0160; Table [3](#Tab3){ref-type="table"}). Other hr.-HPV (i.e. non-HPV 16/18) types were detected in 28% of tissue samples (95% CI: 18--40) and these included HPV 26, 31, 33, 35, 39, 45, 51, 52, 66 and 68 (Fig. [1](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). The highest prevalence of other hr.-HPV types was observed in penile SCC at 46% (6/13), followed by anal SCC at 39% (5/13) and the lowest in vulvar SCC at 19% (8/42). Co-infection with HPV 16 and other hr.-HPV types was only observed in patients with penile SCC (15%; 2/13).Table 2Laboratory characteristics of the study participants stratified according tumor anatomical site. Results are expressed as count and proportion (*N* = 126)Anatomical site/ HPVAnalMales *n* = 8Females *n* = 13Penile *n* = 31Vulvar *n* = 74HPV prevalence4/8 (50.0%)9/13 (69.2%)13/31 (41.9%)42/74 (56.8%)HIV prevalence3/8 (37.5%)9/13 (69.2%)15/31 (48.4%)56/74 (75.7%)HPV-HIV Co-infection rates, %2/3 (66.7%)6/9 (66.7%)8/15 (53.3%)41/56 (55.4%) Table 3Prevalence of high risk-HPV in the study population according to anatomical sites (*N* = 126)Anatomical Site/HPV typeAnal *n* = 21Penile *n* = 31Vulvar *n* = 74All sites *n* = 126*P*-value^b^All hr.-HPV\*HPV+131342680.274HPV-8183258Total213174126%61.941.956.854.0HPV 16 onlyHPV 16+853447HPV 16-58821Total131342680.016%61.538.581.069.1Other hr.-HPV OnlyOther hr.-HPV+56819Other hr.-HPV-873449Total131342680.115%38.546.219.027.9HPV 16 + Other hr.-HPV Co-InfectionCo-Infection0202No Co-Infection13114266Total131342680.068%015.402.9\*HPV 18 was not detected in this study population^a^Fisher's exact *p*-value for comparison of proportion with hr.-HPV by anatomical site^b^Fisher's exact *p*-value for comparison of proportion with HPV 16 only by anatomical site Fig. 1Prevalence of high rsik HPV types in anogenital carcinoma by anatomical site

Multiple-type hr.-HPV infection was detected in 44 of 47 (93.6%) HIV-positive participants co-infected with hr.-HPV. In HIV-negative individuals, only HPV 16 was detected. HPV 18 was not detected in this study.

Discussion {#Sec8}
==========

To our knowledge this is the first report on the prevalence of oncogenic HPV infection in patients with anogenital squamous cell carcinoma (SCC) in Botswana. As expected, the prevalence of HIV co-infection was high, with 89% of the patients with documented HIV status being positive for HIV. This is higher than the HIV prevalence in the general population, which is estimated to be at 24.3% in 15 to 49 years age group in Botswana. The observed high HIV and HPV co-infection in our study is consistent with findings from other studies that have reported an underlying HIV infection as a predisposing factor to acquisition and persistence of oncogenic HPV infection \[[@CR11]--[@CR14], [@CR16]\] in both men and women \[[@CR32], [@CR33]\] but the risk is much higher in men having sex with men (MSM) compared to heterosexual men \[[@CR12], [@CR34], [@CR35]\]. In another study, up to 60% of women with cervical cancer had HIV co-morbidity \[[@CR36]\]. HIV co-infection significantly increases the incidence, prevalence and persistence of HPV infection, and is associated with multiple HPV types \[[@CR37]\]. HIV immunosuppression has also been linked to multiple HPV infections \[[@CR37], [@CR38]\] and the inability to clear HPV infections leading to higher rates of reactivation of latent HPV infections \[[@CR39]\]. This has been attributed to the impaired cell-mediated immunity \[[@CR37], [@CR40]--[@CR42]\].

Although the prevalence of hr.-HPV in this study was high in this population with SCC (54%), it is lower than what has been estimated by cervical cancer studies in Botswana. This could be due to the fact that the previous studies focused on the individuals with HIV infection in Botswana. Ramogola-Masire et al.*,* \[[@CR29]\] reported a 93% prevalence of hr.-HPV in HIV-infected women with cervical intraepithelial neoplasia 2 and 3 (CIN 2 and 3) lesions.

MacLeod et al.*,* \[[@CR30]\] reported 64% hr.-HPV prevalence in HIV-infected women with similar cervical lesions, and in another study, of HIV positive women with invasive cervical cancer (ICC), the prevalence of hr.-HPV was 95% \[[@CR27]\].

Across all anatomical sites, the most frequently observed hr.-HPV type was HPV 16 at 69% and other hr.-HPVs at 28%. This is in keeping with previous studies that have reported HPV 16 as the most commonly isolated genotype in anogenital cancers. The prevalence of HPV 16 was much higher compared to previous studies \[[@CR26], [@CR29], [@CR30]\]. Conversely, other hr.-HPV types had a lower prevalence in our study compared to the previous studies; \[[@CR26], [@CR29]\].

Unlike in the previous studies done on cervical cancer, \[[@CR27], [@CR29], [@CR30]\], HPV 18 was not detected in our study. We also observed HPV types; 26, 31, 45, 51, 66 and 68, which have not been previously reported. Observed differences may be explained in part by the variation in anatomical sites. Statistically, there was no significant difference observed in the oncogenic HPV prevalence amongst the different anatomical sites except that of HPV 16.

A similar study conducted in Myanmar reported an overall hr.-HPV prevalence of 34% in anogenital SCC \[[@CR43]\] whereas in our study hr.-HPV prevalence was 54%, which is much higher. The study found a prevalence of 36.1% for vulvar and 27% for penile SCC respectively \[[@CR43]\]. In contrast to our study, Mu Mu et al.*,* \[[@CR43]\] found that HPV type 16 was the most commonly isolated HPV type in penile SCC whereas in our study other hr.-HPV types were the most common in penile SCC. HPV 18 was not detected in our study.

Prevalence of penile carcinomas carrying hr.-HPV has been reported to range from 30 to 100% \[[@CR44]\] and this is corroborated by our findings. HPV type 16 has been shown to be involved in the pathogenesis of a subset of penile cancer \[[@CR45]\]. This has also been reported by a study in the US that found a high prevalence of HPV 16 among participants with penile cancer \[[@CR46]\] Another study in Uganda found that the most common oncogenic HPV genotypes were 16, 18 and 45 with a prevalence of 46% among penile cancer cases \[[@CR47]\]. A review study of HPV prevalence in SSA also found that South African men had higher rates of HPV 16 in penile cancers \[[@CR48]\].

A proportion of penile cancer cases have also been found to be not associated with HPV 16, as compared to anal and vulvar cancer cases \[[@CR49]\]. This information correlates well with our study findings, as HPV 16 was not the most common HPV type isolated in penile SCC as compared to anal and vulvar SCC. The low HPV 16 prevalence in penile SCC may be due to lower numbers of penile cancers studied and may not reflect the true difference in the proportion of penile SCC attributable to hr.-HPV infection \[[@CR50]\]. Men are also said to clear off HPV infection faster than women \[[@CR51]\].

Women are reported to have higher anal cancer rates than men in the entire population \[[@CR52], [@CR53]\]. This could be the reason why there are more women participants with anal cancer in our study than males. In our study 62% of the anal cancer cases had hr.-HPV genotypes isolated and of these, only 62% had HPV type 16.

However, this information does not correlate with earlier findings by \[[@CR49]\] who reported that about 88% of the anal, vulvar and vaginal cancers are HPV-associated and that 73% of them are attributable to HPV type 16.

HPV 16 and 18 are reported to be the most common genotypes associated with anogenital cancers worldwide. Our findings show that HPV 16 is the most common but HPV 18 is rare.

HPV 16 remains the most prevalent genotype in sub-Saharan Africa with HPV 18 showing lower prevalence than other hr.-HPVs as compared to developed countries \[[@CR54]\]. The availability of bivalent or quadrivalent vaccines that include the low-risk HPV types 6 and 11, represent significant progress in cervical cancer prevention in HIV-negative women. However, our data supports growing epidemiological evidence to suggest that in HIV positive populations, HPV 16 is more frequent, but not predominantly seen in most HIV negative populations \[[@CR40], [@CR55]\]. Therefore there is merit in advancing the development and distribution of polyvalent HPV vaccines that reflects the diversity of HPV genotypes peculiar to African populations as advocated by other studies \[[@CR56]\]. A study in France reported a potential impact of 93% by nonavalent vaccine in preventing hr.-HPV associated anal cancers \[[@CR57]\]. A similar study in Spain also advocated for the new generation vaccine with additional of HPV types as it has potential to prevent almost 90% of hr.-HPV associated female cancers worldwide \[[@CR58]\]. In Botswana, Emerl et al.*,* \[[@CR27]\] has reported a theoretical coverage of 77.8% from 61.8% by the nonavalent vaccine in cervical cancers.

In our study HPV type 16 was the most commonly isolated genotype at 59% but there were other significant hr.-HPV types, which are not covered by the HPV vaccine currently in use in Botswana. Quadrivalent Gardasil© protects against HPV 6, 11, 16 and 18 is currently in use in Botswana but it is only given to young girls aged 9--13 years \[[@CR59], [@CR60]\]. The second-generation HPV vaccines with expanded genotype coverage should be advocated for use in Botswana population.

Our study had limitations; we used available tissue samples in a national reference laboratory bio-repository serving southern region of Botswana population, and this may limit generalization. However, it contributes the first set data in anogenital SCC in Botswana.

HIV status was not available for a small fraction of the samples obtained and although DNA amplification rate was high 92%, using archived FFPE for genotyping requires further investigation. It is plausible that stratifying our data according to age categories could have epidemiological insights. Due to the small sample size per anatomical site, a sub-analysis according to anatomical site and age could not performed.

Conclusions {#Sec9}
===========

Anogenital carcinomas in our study were associated with HPV 16 and other hr.-HPV types. HIV-positive participants had multiple hr.-HPV types detected as compared to HIV-negative participants where only HPV 16 detected. Our study suggests that multivalent vaccines may be more suitable especially for HIV positive individuals. Further studies on possible other causes of anogenital SCC that is not hr.-HPV-associated should be explored, as there were some patients with hr.-HPV negative penile and vulvar SCC.
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